C₂N Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD™ blood test, is a mass spectrometry-based test performed in C₂N’s CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. PrecivityAD™, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. The PrecivityAD™ blood test also has achieved the CE Mark from the European Union. For more information visit www.C2N.com.
View Top Employees from C2N DiagnosticsWebsite | https://www.c2ndiagnostics.com/ |
Employees | 72 (56 on RocketReach) |
Founded | 2007 |
Address | 4340 Duncan Ave, St. Louis, Missouri 63110, US |
Phone | (314) 633-1884 |
Technologies |
JavaScript,
HTML,
Twitter
+6 more
(view full list)
|
Industry | Biotechnology, Medical Testing & Clinical Laboratories, Healthcare, Science and Engineering |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies |
Looking for a particular C2N Diagnostics employee's phone or email?
56 people are employed at C2N Diagnostics.
C2N Diagnostics is based in St. Louis, Missouri.
The NAICS codes for C2N Diagnostics are [5417, 54171, 54, 541714, 541].
The SIC codes for C2N Diagnostics are [87, 873].